Merck & Co.
AWARDS
NEWS
After reviewing available data, Bayer decided to abandon its Phase II development of eliapixant as the benefit-risk profile was not worthwhile.
The researchers believe Keytruda and possibly other anti-PD-1 checkpoint inhibitors might help the immune system track the last signs of HIV while also preventing HIV’s ability to hide.
After guiding the commercial rollout of embattled Alzheimer’s drug Aduhelm for Biogen, Johanna Rossell has departed the company for a leadership role at Enzyvant.
Vaccinex announced positive interim response data in a Phase Ib study assessing pepinemab in combination with Merck’s vaunted checkpoint inhibitor, Keytruda.
Sixty-three percent of patients met the primary endpoint of a 2-point or greater improvement in disease severity without worsening of fibrosis.
The U.S. Food and Drug Administration issued a Complete Response Letter to Merck & Co. for its New Drug Application for gefapixant for refractory chronic cough or unexplained chronic cough.
JOBS
IN THE PRESS